Loading...
>Get to know Trisonim®
Get to know Trisonim®2019-08-09T21:21:49+00:00

During a woman’s pregnancy, there are several checkpoints to determine, to the extent possible, whether the fetus can develop a disease. At NIMGenetics we want to accompany you at this stage.

The combined screening of the first trimester is focused on the Down, Edwards and Patau syndromes (trisomies 21, 18 and 13, respectively). This test consists of a biochemical analysis and an ultrasound (in some cases, two). The result of this process indicates the risk of the baby coming with a genetic anomaly. When this risk exceeds a certain threshold, an invasive test (amniocentesis or chorionic villus biopsy) may be considered.

The great advantage of screening is that it is completely innocuous for the mother and baby, unlike invasive tests, which carry a risk of miscarriage. However, the latter are totally confirmatory tests, while the reliability of the combined screening of the first trimester is considerably lower than that of the invasive tests.

With the recent appearance of the fetal DNA test in maternal blood, the pregnant woman has a screening with a sensitivity close to 100% for trisomies 21, 13 and 18. In this way, these alterations can be discarded with a reliability very similar to that of invasive tests, but without risk.

The exponential advance of these technologies has allowed to give information about other regions of the genome, including microdeletion syndromes. Each of these alterations occurs with a low frequency in the population. However, the likelihood of the baby suffering from any of the microdeletion syndromes, because they constitute a very large group, is relatively high (similar to that of Down syndrome in young women).

NIMGenetics is the first Spanish company to perform the non-invasive fetal DNA test in its facilities, TrisoNIM®, that combines the latest generation of massive sequencing with the most advanced methods of analysis, to provide highly reliable information to provide the peace of mind that any woman seeks in her pregnancy. And without risks.

Our group of experts, led by the President of the Spanish Association of Human Genetics (AEGH) and the Secretary of the Spanish Association of Prenatal Diagnosis (AEDP), have developed three fetal DNA studies to adapt to the needs of each patient:

+ of 50.000

prenatal genetic studies

+ of 20.000

non-invasive prenatal screening test

Why TrisoNIM®?

.

  • SECURITY

It only requires a blood test of the mother, avoiding the risk of spontaneous abortion of amniocentesis.

  • ACCURACY

It combines the latest generation sequencing technology with the most advanced bioinformatic analysis. It employs double analysis algorithm to improve the accuracy, both in the calculation of risk and in the fetal fraction, determining for the reliability of the test. This value is calculated rigorously, in a detailed manner and in accordance with international recommendations.

It has the best technical and medical team specialized in prenatal genetic diagnosis, composed of experts in Medical Genetics and members of the Spanish Association of Prenatal Diagnosis (AEDP) and the Spanish Association> of Human Genetics (AEGH). With the endorsement of the most powerful genomics company worldwide (BGI).

As leaders in the implementation of the most advanced genomic platforms, NIMGenetics is the first company to perform the fetal DNA test in maternal blood entirely in its facilities.

  • TRANQUILITY

The TrisoNIM® range encompasses three types of analysis that differ mainly in the number of syndromes studied. If you want the most complete test, TrisoNIM® Excellence responds to what you are looking for.

A high-risk result after a fetal DNA test must be confirmed by an invasive test. For these cases, NIMGenetics offers you free of charge KaryoNIM® Prenatal, a diagnostic test that analyzes 124 syndromes quickly and effectively.

NIMGenetics has performed more than 50,000 prenatal studies and more than 20,000 fetal DNA tests in maternal blood.

Choose your TrisoNIM®

.

  • Detects fetal trisomies of chromosomes 21, 18 and 13
  • Reports on 3 microdeletion syndromes
  • Reports fetal sex and the most common sex chromosome aneuploidies
  • Results in 7 working days

See file

Button to book your TrisoNIM Advance
  • Detects fetal trisomies of chromosomes 21, 18 and 13
  • Reports on fetal trisomies 9, 16 and 22
  • Reports on 7 microdeletion syndromes
  • Reports fetal sex and the most common sex chromosome aneuploidies
  • Results in 5 working days

See file

Button to book your TrisoNIM Premium
  • Detects fetal trisomies of chromosomes 21, 13 and 18
  • Reports on fetal trisomies 9, 16 and 22
  • Reports on 38 microdeletion syndromes
  • Reports fetal sex and the most common sex chromosome aneuploidies
  • Results in 8 working days

See file

Button to book your TrisoNIM Excellence

How to book your TrisoNIM® test

.

1

Consult your specialist

The specialist will prescribe TrisoNIM if it is considered appropriate, by means of the informed consent of the selected test.

Informed consent

2

Blood extraction

Contact our representatives to guide you through the process and provide you with the sample collection center that best suits your needs.

3

Payment of the test

The payment for TrisoNIM must be made on the day of extraction or the next day. You can pay for the test by bank transfer, deposit account or on our website.

4

Results

NIMGenetics will send the report with the result of your TrisoNIM by E mail.

Any questions?

.

Send us a message

I accept the privacy policy

Do you prefer that we call you?